Semaglutide is compounded due to the following reasons: Accessibility: Due to higher demand for Wegovy and Ozempic, the manufacturer, Novo Nordisk, has experienced on-and-off drug shortages since May 2023
The 5 mg dose is already enough to produce 15% weight loss in most people who respond
It is prescribed as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) that is considered outside a healthy range
Dulaglutide and semaglutide generally cause similar average increases (2-4 beats per minute), with individual responses varying considerably
Contributing factors to age-related decline: Reduced GHRH secretion Increased somatostatin tone Decreased GHSR sensitivity Altered sleep architecture (less deep sleep) Increased adiposity (fat suppresses GH) Consequences of GH Decline The somatopause correlates with many aging-associated changes: Research Rationale for Secretagogues GH secretagogues are researched as potential approaches to age-related decline because they preserve natural regulation (working with, not against, physiological systems), avoid exogenous GH risks (receptor downregulation, supraphysiological levels), maintain pulsatility (preserve natural secretion patterns), and are potentially saferthough this remains to be proven in long-term studies
The term "GLP-1 patch" reflects marketing terminology and consumer search behavior, not verified biological mechanism